APOL1 Genetic Testing in African Americans

Launched by ST. LOUIS UNIVERSITY · Dec 9, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "APOL1 Genetic Testing in African Americans," is studying how certain genetic factors can affect kidney health, particularly in the Black community. Researchers have found that variations in a gene called APOL1 can increase the risk of kidney disease, and they want to learn more about how these genetic differences relate to kidney health and how patients feel about being tested for them. In the first phase of the study, 144 Black patients at Saint Louis University’s clinics were offered genetic testing and shared their thoughts on it. The upcoming phase will expand the study to include more patients and their family members, aiming to better understand how genes and the environment work together and improve care for kidney health.

To participate, patients need to be between 18 and 90 years old and identify as Black or African American. Participants should expect to provide a sample for genetic testing and share their opinions about the process. However, people who are cognitively impaired, terminally ill, or already on kidney replacement therapy cannot join the study. This research could help improve how we predict and manage kidney health risks in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages 18-90
• • Self-Identified as Black/African American. Race will be self-identified. Patients of African ancestry who identify as multi-racial are also eligible to participate.
• Exclusion Criteria:
• • Cognitively impaired/unable to provide consent
• • Terminally ill
• • Renal replacement therapy (RRT), e.g., (but not limited to) hemodialysis, peritoneal dialysis